{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:12:36Z","timestamp":1790871156562,"version":"4.1.0"},"reference-count":37,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["18-14-00044"],"award-info":[{"award-number":["18-14-00044"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Anthrax is a disease caused by Bacillus anthracis that affects mammals, including humans. Recombinant B. anthracis protective antigen (rPA) is the most common basis for modern anthrax vaccine candidates. However, this protein is characterised by low stability due to proteolysis and deamidation. Here, for the first time, two modification variants leading to full-size rPA stabilisation have been implemented simultaneously, through deamidation-prone asparagine residues substitution and by inactivation of proteolysis sites. Obtained modified rPA (rPA83m) has been demonstrated to be stable in various temperature conditions. Additionally, rPA1+2 containing PA domains I and II and rPA3+4 containing domains III and IV, including the same modifications, have been shown to be stable as well. These antigens can serve as the basis for a vaccine, since the protective properties of PA can be attributed to individual PA domains. The stability of each of three modified anthrax antigens has been considerably improved in compositions with tobacco mosaic virus-based spherical particles (SPs). rPA1+2\/rPA3+4\/rPA83m in compositions with SPs have maintained their antigenic specificity even after 40 days of incubation at +37 \u00b0C. Considering previously proven adjuvant properties and safety of SPs, their compositions with rPA83m\/rPA1+2\/rPA3+4 in any combinations might be suitable as a basis for new-generation anthrax vaccines.<\/jats:p>","DOI":"10.3390\/pharmaceutics14040806","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T21:08:22Z","timestamp":1649365702000},"page":"806","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Designing Stable Bacillus anthracis Antigens with a View to Recombinant Anthrax Vaccine Development"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2683-8285","authenticated-orcid":false,"given":"Ekaterina M.","family":"Ryabchevskaya","sequence":"first","affiliation":[{"name":"Department of Virology, Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitriy L.","family":"Granovskiy","sequence":"additional","affiliation":[{"name":"Department of Virology, Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina A.","family":"Evtushenko","sequence":"additional","affiliation":[{"name":"Department of Virology, Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Ivanov","sequence":"additional","affiliation":[{"name":"Department of Virology, Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5134-6624","authenticated-orcid":false,"given":"Olga A.","family":"Kondakova","sequence":"additional","affiliation":[{"name":"Department of Virology, Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9626-2336","authenticated-orcid":false,"given":"Nikolai A.","family":"Nikitin","sequence":"additional","affiliation":[{"name":"Department of Virology, Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0605-9033","authenticated-orcid":false,"given":"Olga V.","family":"Karpova","sequence":"additional","affiliation":[{"name":"Department of Virology, Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"ref_1","unstructured":"Centers for Disease Control and Prevention (CDC) (2001). Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb. Mortal. Wkly. Rep., 50, 909\u2013919."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/scientificamerican1116-11","article-title":"What Lies Beneath","volume":"315","author":"Goudarzi","year":"2016","journal-title":"Sci. Am."},{"key":"ref_3","unstructured":"World Health Organization (WHO) (2022, February 21). Information Sheet Observed Rate of Vaccine Reactions Anthrax Vaccines to Humans. Available online: https:\/\/www.who.int\/vaccine_safety\/initiative\/tools\/Anthrax_Vaccine_rates_information_sheet.pdf?ua=1."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/21645515.2020.1799668","article-title":"Characterization of the UK anthrax vaccine and human immunogenicity","volume":"17","author":"Modi","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1128\/iai.65.12.5171-5175.1997","article-title":"Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs","volume":"65","author":"Little","year":"1997","journal-title":"Infect. Immun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1128\/CVI.00174-12","article-title":"Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant","volume":"19","author":"Wagner","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/14760584.2019.1643242","article-title":"Vaccines against anthrax based on recombinant protective antigen: Problems and solutions","volume":"18","author":"Kondakova","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref_8","first-page":"415","article-title":"Anthrax: Life cycle, mechanisms of pathogenesis and prospects in the development of veterinary vaccines","volume":"56","author":"Kondakova","year":"2021","journal-title":"Agric. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"39897","DOI":"10.1074\/jbc.M508569200","article-title":"Effects of spontaneous deamidation on the cytotoxic activity of the Bacillus anthracis protective antigen","volume":"280","author":"Zomber","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/prot.21432","article-title":"Multiple asparagine deamidation of Bacillus anthracis protective antigen causes charge isoforms whose complexity correlates with reduced biological activity","volume":"68","author":"Powell","year":"2007","journal-title":"Proteins"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.jim.7000239","article-title":"Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis","volume":"28","author":"Ramirez","year":"2002","journal-title":"J. Ind. Microbiol. Biotechnol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1016\/j.vaccine.2018.09.012","article-title":"Improving the stability of recombinant anthrax protective antigen vaccine","volume":"36","author":"Verma","year":"2018","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1128\/IAI.70.3.1653-1656.2002","article-title":"A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection","volume":"70","author":"Walker","year":"2002","journal-title":"Infect. Immun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1128\/CVI.00015-08","article-title":"Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background","volume":"15","author":"Abboud","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/21645515.2020.1772632","article-title":"Two approaches for the stabilization of Bacillus anthracis recombinant protective antigen","volume":"17","author":"Ryabchevskaya","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1016\/j.vaccine.2008.04.052","article-title":"Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform","volume":"26","author":"Denis","year":"2008","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2017.05.006","article-title":"Study of rubella candidate vaccine based on a structurally modified plant virus","volume":"144","author":"Trifonova","year":"2017","journal-title":"Antiviral Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.virol.2013.10.035","article-title":"Biodistribution, pharmacokinetics, and blood compatibility of native and PEGylated tobacco mosaic virus nano-rods and-spheres in mice","volume":"449","author":"Bruckman","year":"2014","journal-title":"Virology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.yrtph.2018.06.010","article-title":"Assessment of structurally modified plant virus as a novel adjuvant in toxicity studies","volume":"97","author":"Nikitin","year":"2018","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.dib.2018.10.102","article-title":"Data in support of toxicity studies of structurally modified plant virus to safety assessment","volume":"21","author":"Nikitin","year":"2018","journal-title":"Data Brief"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"13147","DOI":"10.1073\/pnas.0405405101","article-title":"Structure of heptameric protective antigen bound to an anthrax toxin receptor: A role for receptor in pH-dependent pore formation","volume":"101","author":"Lacy","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","unstructured":"Panina, A.A., Aliev, T.K., Toporova, V.A., Shemchukova, O.B., Biketov, S.F., Dolgikh, D.A., and Sveshnikov, P.G. (December, January 8). Neutralizing antibodies against Bacillus anthracis exotoxin components. Proceedings of the 5th Russian Symposium \u201cProteins and Peptides\u201d, Petrozavodsk, Russia."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3103\/S0096392515040094","article-title":"Obtaining and characterization of spherical particles\u2014New biogenic platforms","volume":"70","author":"Trifonova","year":"2015","journal-title":"Moscow. Univ. Biol. Sci. Bull."},{"key":"ref_24","first-page":"1004","article-title":"Novel approach for designing rotavirus vaccine candidate based on two plant viruses","volume":"55","author":"Ryabchevskaya","year":"2020","journal-title":"Agric. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.meatsci.2015.03.001","article-title":"Enzyme immunoassay and proteomic characterization of troponin I as a marker of mammalian muscle compounds in raw meat and some meat products","volume":"105","author":"Zvereva","year":"2015","journal-title":"Meat. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1016\/j.vaccine.2006.02.013","article-title":"Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits","volume":"24","author":"Ribot","year":"2006","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e00209","DOI":"10.1128\/mBio.00209-18","article-title":"Role of the antigen capture pathway in the induction of a neutralizing antibody response to anthrax protective antigen","volume":"9","author":"Verma","year":"2018","journal-title":"Mbio"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.bbrc.2004.08.020","article-title":"Thermal inactivation of protective antigen of Bacillus anthracis and its prevention by polyol osmolytes","volume":"322","author":"Singh","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ejpb.2012.05.019","article-title":"Biophysical characterization of thermal-induced precipitates of recombinant anthrax protective antigen: Evidence for kinetically trapped unfolding domains in solid-state","volume":"82","author":"Ganesan","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"751091","DOI":"10.1155\/2013\/751091","article-title":"Thermal aggregation of recombinant protective antigen: Aggregate morphology and growth rate","volume":"2013","author":"Belton","year":"2013","journal-title":"J. Biophys."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.micron.2016.10.007","article-title":"Recombinant anthrax protective antigen: Observation of aggregation phenomena by TEM reveals specific effects of sterols","volume":"93","author":"Harris","year":"2017","journal-title":"Micron"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1016\/j.vaccine.2016.06.057","article-title":"Temperature-mediated recombinant anthrax protective antigen aggregate development: Implications for toxin formation and immunogenicity","volume":"34","author":"Sirota","year":"2016","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"10356","DOI":"10.1038\/s41598-020-67023-4","article-title":"Plant virus particles with various shapes as potential adjuvants","volume":"10","author":"Evtushenko","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"845316","DOI":"10.3389\/fmicb.2022.845316","article-title":"Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant","volume":"13","author":"Kovalenko","year":"2022","journal-title":"Front. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1021\/mp2004059","article-title":"Amphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigen","volume":"9","author":"Petersen","year":"2012","journal-title":"Mol. Pharm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1016\/j.vaccine.2021.05.077","article-title":"Single-dose combination nanovaccine induces both rapid and durable humoral immunity and toxin neutralizing antibody responses against Bacillus anthracis","volume":"39","author":"Kelly","year":"2021","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ksenofontov, A.L., Fedorova, N.V., Badun, G.A., Serebryakova, M.V., Nikitin, N.A., Evtushenko, E.A., Chernysheva, M.G., Bogacheva, E.N., Dobrov, E.N., and Baratova, L.A. (2019). Surface characterization of the thermal remodeling helical plant virus. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216905"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/4\/806\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:49:25Z","timestamp":1760136565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/4\/806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["pharmaceutics14040806"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14040806","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,6]]}}}